Skip to medicine information
Protein Simülasyonları ve 3D Modelleme Medicine information · English

Upadacitinib

What upadacitinib is used for

Upadacitinib is an oral Janus kinase inhibitor marketed as Rinvoq. It is prescribed for selected inflammatory conditions, not for pain or itching of unknown cause. The U.S. label covers several rheumatology, dermatology and inflammatory bowel indications, with different age limits and previous-treatment requirements. Giant cell arteritis and selected paediatric arthritis indications are also included. A medicine being licensed for one condition does not make it suitable for another.

Formulation and treatment context

Rinvoq extended-release tablets and Rinvoq LQ oral solution are distinct prescribed presentations. The appropriate product depends on the indication, age and individual circumstances. This summary does not provide starting doses, escalation instructions or a substitution plan. The prescriber should confirm what the dispensed formulation is intended to treat and which accompanying medicines remain appropriate.

Why an interaction review matters

Strong CYP3A4 inhibitors can increase exposure to upadacitinib. Clarithromycin is an example identified in the label. The clinical response is indication-specific: some patients need closer adverse-effect monitoring and some regimens require a prescriber-directed change. Strong CYP3A4 inducers, including rifampin, can reduce exposure and are not recommended with upadacitinib. Other JAK inhibitors and certain potent immunosuppressants are not recommended combinations. Methotrexate is not automatically equivalent to those excluded combinations; its role depends on the underlying indication.

Infection, cardiovascular and laboratory precautions

The prescribing information carries major JAK-inhibitor safety warnings concerning serious infections, malignancies, cardiovascular events, thrombosis and mortality. Individual risk assessment matters, including smoking and cardiovascular history. Screening and follow-up can include tuberculosis, blood counts, liver tests and lipids. Live vaccines should be reviewed before treatment. Prompt assessment is important for fever or a persistent infection, chest pain, sudden breathlessness, one-sided leg swelling, stroke-like symptoms or a serious allergic reaction.

Other practical safety questions

New or severe abdominal pain requires prompt review because gastrointestinal perforations have occurred; the label particularly flags people with relevant history and concomitant NSAIDs or corticosteroids. Pregnancy planning and breastfeeding need a separate discussion. Reported adverse effects differ between conditions and can include respiratory infections, nausea, cough, fever and acne. Check nonprescription medicines and supplements with the pharmacist, and do not stop or change an established regimen solely because a website lists a potential interaction.

Sources and scope

This English summary describes the referenced U.S. product information; local authorisations, age limits and formulations may differ. It is not a dosing guide or an independent clinical review. A missing interaction entry does not establish safety.